Chang 2005.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 354, breast cancer (stage I‐IV); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 40000 IU sc weekly hb‐target = 12‐14 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: QoL; secondary: maintain Hb above 12 g/dL, tumor response, overall survival
Notes	study number = 99137
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization